The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates
Open accessAbstract
Spinal muscular atrophy (SMA) is a debilitating neuromuscular disease caused by the loss of survival of motor neuron (SMN) protein. Previously, we demonstrated that ISIS 396443, an antisense oligonucleotide (ASO) targeted to the SMN2 pre-mRNA, is a potent inducer of SMN2 exon 7 inclusion and SMN protein expression, and improves function and survival of mild and severe SMA mouse models. Here, we demonstrate that ISIS 396443 is the most potent ASO in central nervous system (CNS) tissues of adult mice, compared with several other chemically modified ASOs. We evaluated methods of ISIS 396443 delivery to the CNS and characterized its pharmacokinetics and pharmacodynamics in rodents and nonhuman primates (NHPs). Intracerebroventricular bolus injection is a more efficient method of delivering ISIS 396443 to the CNS of rodents, compared with i.c.v. infusion. For both methods of delivery, the duration of ISIS 396443-mediated SMN2 splicing correction is long lasting, with maximal effects still observed 6 months after treatment discontinuation. Administration of ISIS 396443 to the CNS of NHPs by a single intrathecal bolus injection results in widespread distribution throughout the spinal cord. Based upon these preclinical studies, we have advanced ISIS 396443 into clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many modifications can be applied to microRNA inhibitors and mimics, improving their stability, permeability, and specificity.”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [195]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“intrathecal ASO injection to nonhuman primates led to accumulation of ASO in the cortical neuronal and glial cells (Rigo et al., 2014).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Rigo et al., 2014
The cited source says what the claim attributes to it.
In the citing paper
“Notably, intrathecal antisense oligonucleotides (ASO) injection successfully delivered ASO to the cortical cells in nonhuman primates [142].”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [142]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
RetractedIdentification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Bénichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,995
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,536
Bennett, C. F., & Swayze, E. E. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,431
Self-citationCorrelation between severity and SMN protein level in spinal muscular atrophy
Lefebvre, S., Burlet, P., Liu, Q., Bertrandy, S., Clermont, O., Münnich, A., Dreyfuss, G., & Melki, J. (1997) · Nature Genetics · doi:10.1038/ng0797-265 · Cited by 1,100
Lunn, M. R., & Wang, C. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60921-6 · Cited by 1,010
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,005
Monani, U. R. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.7.1177 · Cited by 951
Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Self-citationMonani, U. R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.3.333 · Cited by 745
Cited by
Sorted by citations
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J., Montes, J., Vivo, D. C. D., Yamashita, M., Rigo, F., Hung, G., Schneider, E., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31408-8 · Cited by 1,039
Self-citationPharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D. A., Yu, R. Z., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 866
Self-citationCrooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationPatient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
Kim, J., Hu, C., Achkar, C. M. E., Black, L. E., Douville, J., Larson, A. A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813279 · Cited by 852
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Roles and mechanisms of alternative splicing in cancer — implications for care
Bonnal, S., López‐Oreja, I., & Valcárcel, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0350-x · Cited by 760
Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophy
Chiriboga, C. A., Swoboda, K. J., Darras, B. T., Iannaccone, S. T., Montes, J., Vivo, D. C. D., Norris, D. A., Bennett, C. F., & Bishop, K. M. (2016) · Neurology · doi:10.1212/wnl.0000000000002445 · Cited by 613
Self-citationAntisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H. T. T., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 586
Splice-switching antisense oligonucleotides as therapeutic drugs
Havens, M. A., & Hastings, M. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw533 · Cited by 552
Towards a therapy for Angelman syndrome by targeting a long non-coding RNA
Meng, L., Ward, A. J., Chun, S. J., Bennett, C. F., Beaudet, A. L., & Rigo, F. (2014) · Nature · doi:10.1038/nature13975 · Cited by 537
Self-citationThe physiology of alternative splicing
Marasco, L. E., & Kornblihtt, A. R. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00545-z · Cited by 550
SMN2 splice modulators enhance U1–pre-mRNA association and rescue SMA mice
Palacino, J., Swalley, S. E., Song, C., Cheung, A. K., Shu, L., Zhang, X., Van Hoosear, M., Shin, Y., Chin, D. N., Keller, C. G., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1837 · Cited by 432
Pharmacology of Antisense Drugs
Bennett, C. F., Baker, B. F., Pham, N. C., Swayze, E. E., & Geary, R. S. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 445
Self-citationRNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A., Choi, Y. H., & Tu, M. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 421
Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
Bennett, C. F., Krainer, A. R., & Cleveland, D. W. (2019) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070918-050501 · Cited by 353
Self-citationAntisense oligonucleotides in therapy for neurodegenerative disorders
Evers, M. M., Toonen, L. J. A., & van Roon‐Mom, W. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.008 · Cited by 297
Treating Disease at the RNA Level with Oligonucleotides
Levin, A. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1705346 · Cited by 287
Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases
Schoch, K. M., & Miller, T. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.010 · Cited by 274
Zhao, H. T., John, N., Delic, V., Ikeda-Lee, K., Kim, A., Weihofen, A., Swayze, E. E., Kordasiewicz, H. B., West, A. B., & Volpicelli‐Daley, L. A. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.08.002 · Cited by 217
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Aartsma-Rus, A. M. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0665 · Cited by 196
Post-transcriptional regulation of gene expression and human disease
Corbett, A. H. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2018.02.011 · Cited by 202
Oligonucleotide therapies for disorders of the nervous system
Khorkova, O., & Wahlestedt, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3784 · Cited by 179
Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide
Tran, H., Moazami, M. P., Yang, H., McKenna-Yasek, D., Douthwright, C. L., Pinto, C., Metterville, J., Shin, M., Sanil, N., Dooley, C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01557-6 · Cited by 174
Kapeli, K., Pratt, G. A., Vu, A. Q., Hutt, K. R., Martinez, F. J., Sundararaman, B., Batra, R., Freese, P., Lambert, N. J., Huelga, S. C., et al. (2016) · Nature Communications · doi:10.1038/ncomms12143 · Cited by 176
Self-citationChaytow, H., Faller, K. M. E., Huang, Y.-T., & Gillingwater, T. H. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100346 · Cited by 179
Zhao, H. T., Damle, S. S., Ikeda-Lee, K., Kuntz, S., Li, J., Mohan, A., Kim, A., Hung, G., Scheideler, M. A., Scherer, S. S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci96499 · Cited by 163
Self-citationOpportunities and challenges for antisense oligonucleotide therapies
Kuijper, E. C., Bergsma, A. J., Pijnappel, W. W. M. P., & Aartsma-Rus, A. M. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12251 · Cited by 157
Delivery is key: lessons learnt from developing splice‐switching antisense therapies
Godfrey, C., Desviat, L. R., Smedsrød, B. H., Piétri‐Rouxel, F., Denti, M. A., Disterer, P., Lorain, S., Nogales‐Gadea, G., Sardone, V., Anwar, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607199 · Cited by 151
Antisense oligonucleotides extend survival of prion-infected mice
Raymond, G. J., Zhao, H. T., Race, B., Raymond, L. D., Williams, K., Swayze, E. E., Graffam, S., Le, J., Caron, T. J., Stathopoulos, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.131175 · Cited by 148
Hua, Y., Liu, Y. H., Sahashi, K., Rigo, F., Bennett, C. F., & Krainer, A. R. (2015) · Genes & Development · doi:10.1101/gad.256644.114 · Cited by 148
Self-citationDelivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology
Pardridge, W. M. (2017) · BioDrugs · doi:10.1007/s40259-017-0248-z · Cited by 152
Minikel, E. V., Zhao, H. T., Le, J., O’Moore, J., Pitstick, R., Graffam, S., Carlson, G. A., Kavanaugh, M. P., Križ, J., Kim, J. B., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa616 · Cited by 144
Nagata, T., Dwyer, C. A., Yoshida‐Tanaka, K., Ihara, K., Ohyagi, M., Kaburagi, H., Miyata, H., Ebihara, S., Yoshioka, K., Ishii, T., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00972-x · Cited by 142
Self-citationSpinal muscular atrophy—recent therapeutic advances for an old challenge
Faravelli, I., Nizzardo, M., Comi, G. P., & Corti, S. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.77 · Cited by 138
RNA‐based medicine: from molecular mechanisms to therapy
Sparmann, A., & Vogel, J. (2023) · The EMBO Journal · doi:10.15252/embj.2023114760 · Cited by 151
Hinrich, A. J., Jodelka, F. M., Chang, J. L., Brutman, D., Bruno, A. M., Briggs, C. A., James, B. D., Stutzmann, G. E., Bennett, D. A., Miller, S. A., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505846 · Cited by 127
Self-citationmicroRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain
Kim, J., Yoon, H., Horie, T., Burchett, J. M., Restivo, J. L., Rotllan, N., Ramírez, C. M., Verghese, P. B., Ihara, M., Hoe, H.-S., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2053-15.2015 · Cited by 128
Jafar-nejad, P., Powers, B., Soriano, A., Zhao, H., Norris, D. A., Matson, J., DeBrosse-Serra, B., Watson, J., Narayanan, P., Chun, S. J., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1235 · Cited by 128
Self-citationPandey, S., Wheeler, T. M., Justice, S. L., Kim, A., Younis, H. S., Gattis, D., Jauvin, D., Puymirat, J., Swayze, E. E., Freier, S. M., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.226969 · Cited by 126
Self-citationHuntingtin suppression restores cognitive function in a mouse model of Huntington’s disease
Southwell, A. L., Kordasiewicz, H. B., Langbehn, D., Skotte, N. H., Parsons, M. P., Villanueva, E. B., Caron, N. S., Østergaard, M. E., Anderson, L. M., Xie, Y., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3959 · Cited by 126
Self-citationBiological applications of xeno nucleic acids
Morihiro, K., Kasahara, Y., & Obika, S. (2016) · Molecular BioSystems · doi:10.1039/c6mb00538a · Cited by 119
Skotte, N. H., Southwell, A. L., Østergaard, M. E., Carroll, J. B., Warby, S. C., Doty, C. N., Petoukhov, E., Vaid, K., Kordasiewicz, H. B., Watt, A. T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107434 · Cited by 120
Self-citationBrain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging
Mazur, C., Powers, B., Zasadny, K., Sullivan, J. M., Dimant, H., Kamme, F., Hesterman, J., Matson, J., Oestergaard, M., Seaman, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129240 · Cited by 114
Self-citationKeiser, M. S., Kordasiewicz, H. B., & McBride, J. L. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv442 · Cited by 117
Li, M., Jancovski, N., Jafar-Nejad, P., Burbano, L. E., Rollo, B., Richards, K., Drew, L., Sedo, A., Heighway, J., Pachernegg, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152079 · Cited by 115
Self-citationA Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna
Taghian, T., Marosfoi, M. G., Puri, A. S., Cataltepe, O. I., King, R. M., Diffie, E. B., Maguire, A. S., Martin, D. R., Fernau, D., Batista, A. R., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.012 · Cited by 111
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion
Shadid, M., Badawi, M. A., & Abulrob, A. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1992382 · Cited by 123
Antisense drugs make sense for neurological diseases
Bennett, C. F., Kordasiewicz, H. B., & Cleveland, D. W. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023738 · Cited by 108
Self-citationQiu, P., Zhou, Y., Oyang, L., Wu, N., Tang, Y., Su, M., Luo, X., Wang, Y., Sheng, X., Ma, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.010 · Cited by 109
Takakusa, H., Iwazaki, N., Nishikawa, M., Yoshida, T., Obika, S., & Inoué, T. (2023) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0054 · Cited by 102
Scharner, J., & Aznarez, I. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.022 · Cited by 96
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides
Goyenvalle, A., Jimenez-Mallebrera, C., van Roon‐Mom, W., Sewing, S., Krieg, A. Μ., Arechavala‐Gomeza, V., & Andersson, P. U. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0061 · Cited by 102
Wang, Y., Yu, R. Z., Henry, S. P., & Geary, R. S. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1621838 · Cited by 104
Self-citationHarnessing cerebrospinal fluid circulation for drug delivery to brain tissues
Naseri Kouzehgarani, G., Feldsien, T., Engelhard, H. H., Mirakhur, K. K., Phipps, C., Nimmrich, V., Clausznitzer, D., & Lefebvre, D. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.002 · Cited by 95
Dindot, S. V., Christian, S., Murphy, W. J., Berent, A., Panagoulias, J., Schlafer, A., Ballard, J. L., Radeva, K., Robinson, R., Myers, L. S., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abf4077 · Cited by 97
Toonen, L. J. A., Rigo, F., van Attikum, H., & van Roon‐Mom, W. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.06.019 · Cited by 92
Self-citationTsoumpra, M. K., Fukumoto, S., Matsumoto, T., Takeda, S., Wood, M. J. A., & Aoki, Y. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.036 · Cited by 93
Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders
Hill, S. F., & Meisler, M. H. (2021) · Developmental Neuroscience · doi:10.1159/000517686 · Cited by 91
Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain
Sumner, C. J., & Crawford, T. O. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121658 · Cited by 92
Towards a treatment for genetic prion disease: trials and biomarkers
Vallabh, S. M., Minikel, E. V., Schreiber, S. L., & Lander, E. S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30403-x · Cited by 88
Pharmacology of Modulators of Alternative Splicing
Bates, D. O., Morris, J. C., Oltean, S., & Donaldson, L. F. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011239 · Cited by 83
Solé, G., Salort‐Campana, E., Péréon, Y., Stojkovic, T., Wahbi, K., Cintas, P., Adams, D., Laforêt, P., Tiffreau, V., Desguerre, I., et al. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.04.004 · Cited by 84
Bishop, K. M., Montes, J., & Finkel, R. S. (2017) · Muscle & Nerve · doi:10.1002/mus.25705 · Cited by 83
Luo, X., Fitzsimmons, B., Mohan, A., Zhang, L., Terrando, N., Kordasiewicz, H. B., & Ji, R. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.11.007 · Cited by 82
Characterization of the Prion Protein Binding Properties of Antisense Oligonucleotides
Reidenbach, A. G., Minikel, E. V., Zhao, H. T., Guzman, S., Leed, A., Mesleh, M. F., Kordasiewicz, H. B., Schreiber, S. L., & Vallabh, S. M. (2019) · Biomolecules · doi:10.3390/biom10010001 · Cited by 82
Sheng, L., Rigo, F., Bennett, C. F., Krainer, A. R., & Hua, Y. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa126 · Cited by 84
Self-citationWong, H. K., Fatimy, R. E., Onodera, C. S., Wei, Z., Yi, M., Mohan, A., Gowrisankaran, S., Karmali, P. P., Marcusson, E. G., Wakimoto, H., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.72 · Cited by 80
Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm
Grabowska, W., Want, A., Leszek, J., & Wojda, U. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103691 · Cited by 81
Non-coding RNAs in Nervous System Development and Disease
Salvatori, B., Biscarini, S., & Morlando, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00273 · Cited by 74
In vivo and in vitro studies of antisense oligonucleotides – a review
Kilanowska, A., & Studzińska, S. (2020) · RSC Advances · doi:10.1039/d0ra04978f · Cited by 76
Mendonça, M. C. P., Kont, A., Aburto, M. R., Cryan, J. F., & O’Driscoll, C. M. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c01238 · Cited by 75
Oligonucleotide therapeutics in neurodegenerative diseases
Scoles, D. R., & Pulst, S. M. (2018) · RNA Biology · doi:10.1080/15476286.2018.1454812 · Cited by 72
Silva, A. C., Lobo, D. D., Martins, I. M., Lopes, S., Henriques, C., Duarte, S., Dodart, J., Nobre, R. J., & de Almeida, L. P. (2019) · Brain · doi:10.1093/brain/awz328 · Cited by 73
Hensel, N., Kubinski, S., & Claus, P. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00045 · Cited by 76
Marasco, L. E., Dujardin, G., Sousa‐Luís, R., Liu, Y. H., Stigliano, J. N., Nomakuchi, T. T., Proudfoot, N. J., Krainer, A. R., & Kornblihtt, A. R. (2022) · Cell · doi:10.1016/j.cell.2022.04.031 · Cited by 71
Self-citationHammond, S. M., Abendroth, F., Goli, L., Burrell, M., Thom, G., Gurrell, I., Stoodley, J., Ahlskog, N., Gait, M. J., Wood, M. J. A., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.154142 · Cited by 80
Monine, M. I., Norris, D. A., Wang, Y., & Nestorov, I. A. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09761-0 · Cited by 70
Self-citationOpportunities and challenges for microRNA-targeting therapeutics for epilepsy
Morris, G., O’Brien, D., & Henshall, D. C. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.04.007 · Cited by 67
LRRK2 Targeting Strategies as Potential Treatment of Parkinson’s Disease
Wojewska, D., & Kortholt, A. (2021) · Biomolecules · doi:10.3390/biom11081101 · Cited by 64
Bogdanik, L. P., Osborne, M. A., Davis, C., Martin, W., Austin, A., Rigo, F., Bennett, C. F., & Lutz, C. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509758112 · Cited by 63
Self-citationShabanpoor, F., Hammond, S. M., Abendroth, F., Hazell, G., Wood, M. J. A., & Gait, M. J. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0652 · Cited by 64
RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions
MacLeod, A. R., & Crooke, S. T. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.957 · Cited by 61
Godinho, B. M. D. C., Henninger, N., Bouley, J., Alterman, J. F., Haraszti, R. Á., Gilbert, J. W., Sapp, E., Coles, A. H., Biscans, A., Nikan, M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.005 · Cited by 60
RAB10: an Alzheimer’s disease resilience locus and potential drug target
Tavana, J., Rosene, M., Jensen, N., Ridge, P. G., Kauwe, J. S. K., & Karch, C. M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s159148 · Cited by 62
Luu, K. T., Norris, D. A., Gunawan, R., Henry, S. P., Geary, R. S., & Wang, Y. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.884 · Cited by 59
Self-citationNusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
Li, Q. (2020) · Yonsei Medical Journal · doi:10.3349/ymj.2020.61.4.273 · Cited by 67
Szabó, L., Gergely, A., Jakus, R., Fogarasi, A., Grosz, Z., Molnár, M. J., Andor, I., Schulcz, O., Goschler, Á., Medveczky, E., et al. (2020) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2020.05.002 · Cited by 61
A single-cell map of antisense oligonucleotide activity in the brain
Mortberg, M. A., Gentile, J. E., Nadaf, N. M., Vanderburg, C., Simmons, S., Dubinsky, D., Slamin, A., Maldonado, S., Petersen, C. L., Jones, N., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad371 · Cited by 54
Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics
Zhou, T., Kim, Y., & MacLeod, A. R. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3378-5_16 · Cited by 53
van Roon‐Mom, W., Ferguson, C. M., & Aartsma-Rus, A. M. (2023) · Nucleic Acid Therapeutics · doi:10.1089/nat.2023.0027 · Cited by 51
Chang, J. L., Hinrich, A. J., Roman, B., Norrbom, M., Rigo, F., Marr, R. A., Norstrom, E. M., & Hastings, M. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.029 · Cited by 53
Self-citationCheng, H., Chern, Y., Chen, I.-H., Liu, C.-R., Li, S.-H., Chun, S. J., Rigo, F., Bennett, C. F., Deng, N., Feng, Y., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005043 · Cited by 50
Self-citationKorecka, J. A., Thomas, R., Hinrich, A. J., Moskites, A., Macbain, Z. K., Hallett, P. J., Ole Isacson, A., & Hastings, M. L. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.06.027 · Cited by 49
Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease
Centa, J. L., Jodelka, F. M., Hinrich, A. J., Johnson, T. B., Ochaba, J., Jackson, M., Duelli, D. M., Weimer, J. M., Rigo, F., & Hastings, M. L. (2020) · Nature Medicine · doi:10.1038/s41591-020-0986-1 · Cited by 47
Self-citationHistory of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
Qiu, J., Wu, L., Qu, R., Jiang, T., Bai, J., Sheng, L., Feng, P., & Sun, J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.942976 · Cited by 49
Benichou, S. A., Jauvin, D., Serres‐Bérard, T. D., Pierre, M., Ling, K., Bennett, C. F., Rigo, F., Gourdon, G., Chahine, M., & Puymirat, J. (2022) · Gene Therapy · doi:10.1038/s41434-022-00316-7 · Cited by 48
Self-citationBunting, E. L., Donaldson, J., Cumming, S. A., Olive, J. F., Broom, E. L., Miclăuș, M., Hamilton, J., Tegtmeyer, M., Zhao, H. T., Brenton, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adn4600 · Cited by 48
Splicing modulation therapy in the treatment of genetic diseases
Aartsma-Rus, A. M., Arechavala‐Gomeza, V., & Khoo, B. C. E. (2014) · The Application of Clinical Genetics · doi:10.2147/tacg.s71506 · Cited by 51
Mohan, A., Fitzsimmons, B., Zhao, H. T., Jiang, Y., Mazur, C., Swayze, E. E., & Kordasiewicz, H. B. (2017) · Pain · doi:10.1097/j.pain.0000000000001074 · Cited by 54
Metadata
- Authors
- Rigo, F., Chun, S. J., Norris, D. A., Hung, G., Lee, S., Matson, J., Fey, R. A., Gaus, H., Hua, Y., Grundy, J. S., Krainer, A. R., Henry, S. P., & Bennett, C. F.
- Affiliations
- Cold Spring Harbor Laboratory (US)
- ORCID
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 350
- Issue
- 1
- Pages
- 46-55
- ISSN
- 0022-3565 (ISSN-L)
- PMC
- PMC4056267
- OpenAlex
- W2090804804
- Cited by
- 283
- References
- 56
- Citations by year
- 2026: 16 · 2025: 19 · 2024: 22 · 2023: 25 · 2022: 24 · 2021: 25 · 2020: 35 · 2019: 24 · 2018: 23 · 2017: 23 · 2016: 21 · 2015: 21 · 2014: 5
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Funders
- Spinal Muscular Atrophy Foundation
- National Institute of General Medical Sciences (R37-GM42699, R37GM042699, R01GM042699)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, antisense oligonucleotides, SMN protein, central nervous system delivery, intrathecal administration, pharmacokinetics, pharmacodynamics, non-human primates, modified oligonucleotides, preclinical pharmacology
- MeSH terms
- Animals, Brain, Female, Injections, Intraventricular, Macaca fascicularis, Male, Muscular Atrophy, Spinal, Oligonucleotides, RNA Splicing, Mice, Knockout, Oligodeoxyribonucleotides, Antisense, Mice, Survival of Motor Neuron 2 Protein, Infusions, Intraventricular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
